1-(4-bromo-2-chlorophenyl)pyrrolidine | 1352216-52-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-(4-bromo-2-chlorophenyl)pyrrolidine
• CAS: 1352216-52-4
• 化学式: C₁₀H₁₁BrClN
• 分子量: 260.561
• InChiKey: LTWXVSBFADHJNQ-UHFFFAOYSA-N

物化性质

• 沸点：
  331.7±32.0 °C(Predicted)
• 密度：
  1.514±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(4-bromo-2-chlorophenyl)pyrrolidine 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 四(三苯基膦)钯 、 potassium acetate 、 potassium carbonate 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 二甲基亚砜 为溶剂， 20.0~90.0 ℃ 、500.01 kPa 条件下， 反应 52.0h， 生成 6-(3-chloro-4-(pyrrolidin-1-yl)phenyl)pyrimidine-4-carboxylic acid
  参考文献：
  名称：

  Development of a Series of Aryl Pyrimidine Kynurenine Monooxygenase Inhibitors as Potential Therapeutic Agents for the Treatment of Huntington’s Disease

  摘要：

  We report on the development of a series of pyrimidine carboxylic acids that are potent and selective inhibitors of kynurenine monooxygenase and competitive for kynurenine. We describe the SAR for this novel series and report on their inhibition of KMO activity in biochemical and cellular assays and their selectivity against other kynurenine pathway enzymes. We describe the optimization process that led to the identification of a program lead compound with a suitable ADME/PK profile for therapeutic development. We demonstrate that systemic inhibition of KMO in vivo with this lead compound provides pharmacodynamic evidence for modulation of kynurenine pathway metabolites both in the periphery and in the central nervous system.

  DOI：

  10.1021/jm501350y
• 作为产物：
  描述：

  1,4-二溴丁烷 、 4-溴-2-氯苯胺 在 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 以45%的产率得到1-(4-bromo-2-chlorophenyl)pyrrolidine
  参考文献：
  名称：

  [EN] KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
  [FR] INHIBITEURS DE KYNURÉNINE-3-MONOOXYGÉNASE, COMPOSITIONS PHARMACEUTIQUES ET PROCÉDÉS D'UTILISATION DE CES COMPOSITIONS

  摘要：

  本文提供了某些化学实体。还提供了包括至少一种化学实体和一种或多种药用载体的药物组合物。描述了治疗对KMO活性抑制敏感的某些疾病和疾病的方法，包括向这些患者投与至少一种化学实体的有效量以减轻疾病或疾病症状的方法。这些疾病包括亨廷顿病等神经退行性疾病。还描述了治疗方法，包括单独使用至少一种化学实体或将至少一种化学实体与一种或多种其他治疗剂结合使用的方法。还提供了筛选能够抑制KMO活性的化合物的方法。

  公开号：

  WO2013033085A1

文献信息

• A Biomass-Derived Non-Noble Cobalt Catalyst for Selective Hydrodehalogenation of Alkyl and (Hetero)Aryl Halides
  作者：Basudev Sahoo、Annette-Enrica Surkus、Marga-Martina Pohl、Jörg Radnik、Matthias Schneider、Stephan Bachmann、Michelangelo Scalone、Kathrin Junge、Matthias Beller

  DOI：10.1002/anie.201702478

  日期：2017.9.4

  straightforward approach for detoxifications of harmful anthropogenic organohalide-based pollutants, as well as removal of halide protecting groups used in multistep syntheses. A novel sustainable catalytic material was prepared from biowaste (chitosan) in combination with an earth-abundant cobalt salt. The heterogeneous catalyst was fully characterized by transmission electron microscope, X-ray diffraction,

  加氢脱卤是一种直接的方法，可以对有害的人为有机卤化物进行排毒，并去除多步合成中使用的卤化物保护基。一种新型的可持续催化材料是由生物废料（壳聚糖）与富含地球的钴盐结合制成的。通过透射电子显微镜，X射线衍射和X射线光电子能谱测量对多相催化剂进行了充分表征，并将其成功应用于烷基卤和（杂）芳基卤化物的加氢脱卤，适用范围广（> 40个实例），并且具有出色的化学选择性氢作为还原剂。这种方法的普遍用途通过不可降解农药和阻燃剂的成功排毒得到证明。而且，
• [EN] NITROGEN-CONTAINING BIOPOLYMER-BASED CATALYSTS, THEIR PREPARATION AND USES IN HYDROGENATION PROCESSES, REDUCTIVE DEHALOGENATION AND OXIDATION<br/>[FR] CATALYSEURS À BASE DE BIOPOLYMÈRES CONTENANT DE L'AZOTE, LEUR PRÉPARATION ET LEURS UTILISATIONS DANS DES PROCÉDÉS D'HYDROGÉNATION, DÉSHALOGÉNATION RÉDUCTRICE ET OXYDATION
  申请人：HOFFMANN LA ROCHE

  公开号：WO2018114777A1

  公开（公告）日：2018-06-28

  The present invention relates to a process for the preparation of a nitrogen containing biopolymer-based catalyst by pyrolysis of a metal complex with a nitrogen-containing biopolymer and to the nitrogen containing biopolymer-based catalysts obtainable by this process. In particular, the invention relates to a nitrogen containing biopolymer-based catalyst comprising metal particles and at least one nitrogen containing carbon layer. The invention also relates to the use of a nitrogen containing biopolymer-based catalyst in a hydrogenation process, preferably in a process for hydrogenation of nitroarenes, nitriles or imines; in a reductive dehalogenation process of C-X bonds, wherein X is CI, Br or I, preferably in a process for dehalogenation of organohalides or in a process for deuterium labelling of arenes via dehalogenation of organohalides; or in an oxidation process. Further, the invention relates to a metal complex with the nitrogen containing biopolymer, wherein the metal is a transition metal selected from the group consisting of manganese, ruthenium, cobalt, rhodium, nickel, palladium and platinum, preferably cobalt or nickel, and wherein the nitrogen containing biopolymer is selected from chitosan, chitin and a polyamino acid, preferably chitosan or chitin.

  本发明涉及一种通过金属配合物与含氮生物聚合物的热解制备含氮生物聚合物基催化剂的方法，以及通过该方法获得的含氮生物聚合物基催化剂。具体而言，本发明涉及一种含金属颗粒和至少一层含氮碳层的含氮生物聚合物基催化剂。该发明还涉及在氢化过程中使用含氮生物聚合物基催化剂，优选在对硝基苯胺、腈或亚胺进行氢化的过程中使用；在C-X键的还原去卤化过程中使用，其中X为Cl、Br或I，优选在有机卤化物去卤化过程中使用，或者在通过有机卤化物的去卤化对芳烃进行氘标记的过程中使用；或者在氧化过程中使用。此外，本发明涉及一种与含氮生物聚合物配合的金属配合物，其中金属是锰、钌、钴、铑、镍、钯和铂中选择的过渡金属，优选钴或镍，而含氮生物聚合物选择自壳聚糖、壳聚糖和聚氨基酸，优选壳聚糖或壳聚糖。
• KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：Courtney Stephen Martin

  公开号：US20160251318A1

  公开（公告）日：2016-09-01

  Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

  本文提供了某些化学实体。还提供了包含至少一种化学实体和一个或多个药用载体的制药组合物。描述了治疗对KMO活性抑制有反应的某些疾病和障碍的患者的方法，其中包括向这些患者施用至少一种化学实体的有效量，以减轻疾病或障碍的症状。这些疾病包括神经退行性疾病，如亨廷顿病。还描述了治疗方法，包括单独使用至少一种化学实体作为活性药剂或与一个或多个其他治疗剂联合使用至少一种化学实体。此外，还提供了筛选能够抑制KMO活性的化合物的方法。
• US9981918B2
  申请人：——

  公开号：US9981918B2

  公开（公告）日：2018-05-29